ClinicalTrials.gg
Enrolling by invitationNCT06648564periimpl20yUpdated Jun 29, 2026

20-25 Year Follow-Up on Regenerative Bone Procedures for Peri-Implantitis

An observational study in Peri-implantitis, sponsored by Kristianstad University. Enrolling by invitation at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Kristianstad University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
20
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Peri-Implantitis with a site in Sweden — 5 open to participants now, 6 under way, none of them phase 3. Peri-Implantitis · Sweden.

Started
2025
the only one that year
Observational
9 of 21
3 open now
Registered
20th of 21
by date
Lead sponsor
2 of 21
Kristianstad University

Among the 21 studies in Peri-Implantitis with a site in Sweden, this one is the only one that started in 2025, is one of 9 observational ones, and was the 20th registered.

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

5 of the 21 studies in Peri-Implantitis with a site in Sweden are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Peri-Implantitis with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this 20-25-year observational study is to investigate the outcomes of bone regenerative surgery in peri-implantitis. Two different techniques will be compared: surgery with a bone substitute alone and surgery with a bone substitute combined with a membrane, to determine their effectiveness and assess whether one is more effective than the other. The intention of this observational study is to learn more about the long-term effects of bone regenerative surgery in patients with peri-implantitis.

Patients will be called in for a clinical and radiographic examination of the surgically treated implant(s). Probing pocket depths, presence of pus, bleeding around the implant (s) and a radiograph of the implant (s).

To be able to compare with the 1, 3, 5 and 10 year measurements.

Read the detailed description

The aim of this 20-25 year observational follow-up study is to investigate the outcomes of bone regenerative surgery in peri-implantitis. The study compares two approaches: Group 1: surgery with a bone substitute alone (Algipore) and Group 2: surgery with a bone substitute (Algipore) combined with a membrane (Osseoquest). Both groups received systemic antibiotics-Amoxicillin 375 mg three times a day combined with Metronidazole 400 mg twice a day for 10 days, starting the day before surgery.

The objective of this observational study is to gain insights into the long-term effects of bone regenerative surgery in patients with peri-implantitis and to determine if there is a difference.

The patients were enrolled in a strict maintenance program with supportive therapy every third months with a yearly evaluation.

In this study, patients will examined of the surgically treated implant(s) after 20-25 years. The examination will include a clinical assessment, measuring probing pocket depths at each implant to the nearest millimeter using a standardized probing force of 0.25 N (Hawe-Click Probe, Kerr Hawe SA Bioggio, Switzerland). The prevalence of pus, full-mouth bleeding on probing, and bleeding grades will be recorded around the implant(s) at four sites per tooth and implant(s) as follows: 0 = no bleeding, 1 = point of bleeding, 2 = line of bleeding, and 3 = drop of bleeding. The plaque index will be defined as either visible or not visible at the implant site using an erythrosine dye (TopDent Lifco Dental AB, Enköping, Sweden). All clinical assessments will be performed by the same periodontist (AMRJ).

Data from the clinical treatment were registered in patient records. In parallel, clinical data were documented in a study protocol and saved in a safe in accordance with standard operation procedure at the clinic.The protocol with medical records were not opened until the study was completed and only by authorized persons with access to the data in the study such as, principal investigator and statisticians.

In accordance with an international working group diagnosis of peri-implantitis should include pocket depth, bleeding, and bone loss (X-ray). Thus, in this study the primary outcomes are radiographic evidence of bone fill and changes in probing depths at implants treated.

Parametric tests (independent t-tests, equal variance not assumed), and non-parametric tests (Mann-Whitney U-test, Wilcoxon test) will be performed to assess differences over time and between groups. Statistical significance will be declared at p \<0.05. The Kolmogorov- Smirnov test will be used to define if the data presented with normal distribution or not. The SPSS PASW 29.0 statistical software (SPSS Inc., Chicago, IL, USA) for Apple computer will be used in the analysis.

Patients that will participate in the study will consecutively be given an ID code. and data will be registered in the ordinary patient journal. The code list will be placed in a locked up space, at the clinic.

All patients will be given oral and written information about the study and will sign a written informed consent. The patients will be informed that they could drop off when ever they want without any explanations. The ethical board approved the study.

03

Conditions studied

  • Peri-implantitis

Browse trials for

Keywords

  • peri-implantitis
  • regenerative surgery
  • long time follow-up
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients diagnosed with at least one dental implant with peri-implantitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An implant demonstrating a progressive bone loss of ≥3 threads (≥1.8 mm) following the first year of healing
  • A vertical component needed to be present at the surgical intervention in order to justify the use of a bone augmentation procedure.
  • Bleeding on probing and/or suppuration should also be present

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1

    Bone regenerativ surgery with a bone graft material (Algipore) and a resorbable membrane (Osseoquest)

    Procedure: Bone regenerative surgery with a bone graft substitute and a resorbable membrane

  • Group 2

    Bone regenerativ surgery with a bone graft material (Algipore)

Interventions

  • ProcedureBone regenerative surgery with a bone graft substitute and a resorbable membrane

    Dental implants with a diagnosis peri-implantitis were treated with regenerative surgery.

    Also known as: Bone regenerative surgery with a bone graft substitute

06

What researchers measure

Primary outcomes

  1. Bone fill

    Radiographic bone fill measured mesial and distal at the implant on an intra oral radiograph. Measurements will be performed by a blinded radiologist.

    Time frame: Ten years after surgical regenerative boneprocedures

Secondary outcomes

  1. Probing pocket depths changes

    Changes in probing pocket depth at the implant measured on 4 surfaces

    Time frame: Ten years after surgical regenerative boneprocedures

Other outcomes

  1. Bleeding

    Bleeding on probing measured at the implant on 4 sites.

    Time frame: Ten years after surgical regenerative boneprocedures

  2. Graded bleeding

    Graded bleeding measured at the implant on 4 sites as: 0 = no bleeding, 1 = point of bleeding, 2 = line of bleeding, and 3 = drop of bleeding.

    Time frame: Ten years after surgical regenerative boneprocedures

07

Study locations

1 site
  • Kristianstad Univeristy
    Kristianstad, 29893, Sweden
08

References and documents

Publications

  • Roos-Jansaker AM, Persson GR, Lindahl C, Renvert S. Surgical treatment of peri-implantitis using a bone substitute with or without a resorbable membrane: a 5-year follow-up. J Clin Periodontol. 2014 Nov;41(11):1108-14. doi: 10.1111/jcpe.12308. Epub 2014 Oct 17. PubMed 25195613 ↗
  • Roos-Jansaker AM, Lindahl C, Persson GR, Renvert S. Long-term stability of surgical bone regenerative procedures of peri-implantitis lesions in a prospective case-control study over 3 years. J Clin Periodontol. 2011 Jun;38(6):590-7. doi: 10.1111/j.1600-051X.2011.01729.x. Epub 2011 Apr 13. PubMed 21488935 ↗
  • Roos-Jansaker AM, Renvert H, Lindahl C, Renvert S. Surgical treatment of peri-implantitis using a bone substitute with or without a resorbable membrane: a prospective cohort study. J Clin Periodontol. 2007 Jul;34(7):625-32. doi: 10.1111/j.1600-051X.2007.01102.x. PubMed 17555414 ↗

Individual participant data

Plan to share: Undecided — May be shared upon request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 33 non-industry observational studies under Peri-Implantitis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 77. This study's planned 16 months is close to that.

Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 8 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2024
First posted
Oct 18, 2024
StartActual
Aug 31, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06648564
Lead sponsor
Kristianstad University
Responsible party
Viveca Wallin Bengtsson (phD, Kristianstad University) — Principal investigator
First posted
Oct 18, 2024
Start date
Aug 31, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 29, 2026

Study contacts

AM R Jansaker, Ass.Prof.
study director · Malmö University
Stefan Renvert, Prof.
study chair · Kristianstad University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion